The report provides a detailed analysis essential for establishing a somatrogon production plant. It encompasses all critical aspects necessary for somatrogon production, including the cost of somatrogon production, somatrogon plant cost, somatrogon production costs, and the overall somatrogon production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a somatrogon production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Somatrogon is a long-acting human growth hormone analogue which is administered once weekly via subcutaneous injection. It is used to treat growth failure in pediatric patients aged 3 years and older because of inadequate endogenous growth hormone secretion (GHD). It mimics natural GH by binding to receptors, activating the STAT5b pathway, and elevating IGF-1 levels. It reduces injection burden, improves adherence, and maintains similar safety for children with pituitary-related GHD. It is approved by the FDA and given in a dose of 0.66 mg/kg per week (max 10 mg) under medical supervision. Its common side effects include injection site reactions, upper respiratory infections, headache, fever, cough, vomiting, abdominal pain, rash, sore throat, anaemia, and joint pain.
The market for somatrogon is driven by increasing cases of pediatric growth hormone deficiency. Its demand for once-weekly long-acting formulations, along with FDA and EMA approvals expanding access in North America, Europe, and the Asia-Pacific region, boosts its market. The increased awareness and diagnostics for rare endocrine disorders, and the global launch strategy targeting endocrinologists fuels its market. The high costs of biologics production via recombinant DNA in CHO cells and reliance on Pfizer as the primary supplier with pre-filled pens influence industrial somatropin procurement. Also, reimbursement challenges in orphan therapy pricing, regulatory biosimilar hurdles post-patent, and supply chain for cold-chain logistics affect its sourcing costs.
Raw Material for Somatrogon Production
According to the somatrogon production plant project report, the key raw materials used in the production of somatrogon include Chinese hamster ovary (CHO) cell line, acetonitrile, ethanol, and sodium hydroxide.
Production Process of Somatrogon
The extensive somatrogon production cost report consists of the following major industrial production process:
- From the Chinese hamster ovary (CHO) cell line: The production of somatrogon begins with upstream fed-batch cell culture of genetically modified CHO cell line in reactor bags. Its harvesting involves depth filtration to remove CHO cells, producing a clarified stream for downstream purification. This includes general purification steps with acetonitrile in reverse-phase chromatography and ethanol in closed-loop buffer preparation. The final product is separated and further purified to get somatrogon.
Somatrogon is a long-acting recombinant human growth hormone (hGH) analogue. It contains a 191-amino-acid hGH sequence with one C-terminal peptide (CTP) from hCG-β at the N-terminus and two tandem CTPs at the C-terminus. This enables O-linked glycosylation for extended half-life (weekly dosing). It appears as a sterile, clear, colourless to slightly light yellow preserved aqueous solution at pH ≈6.6. It is formulated with citric acid monohydrate, L-histidine, m-cresol (preservative), poloxamer 188, sodium chloride, and sodium citrate dihydrate in water for injection. It is available in pre-filled pens at 24 mg/1.2 mL (20 mg/mL) or 60 mg/1.2 mL (50 mg/mL) strengths for subcutaneous use. It shows chemical stability for 28 days in-use under refrigeration.